Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICTUMAB: Omalizumab vs mepolizumab in severe allergic and eosinophilic asthma
2024-516783-29-00Phase 4Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in allergic asthma and eosinophilic asthma (EA) comparing Omalizumab arm with Mepolizumab arm (2 arms). Primary endpoints: Annual rate of severe exacerbations (omalizumab vs mepolizumab, overall population) and Rate of response to omalizumab vs mepolizumab. Started Nov 2024; status: completed.
02
Drugs
omalizumabmepolizumab
03
Conditions
allergic asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2024-516783-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516783-29-00.